Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

OTC Markets Group Welcomes DelMar Pharmaceuticals to OTCQX®

OTCM

NEW YORK, Dec. 2, 2014 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced DelMar Pharmaceuticals, Inc. (OTCQX: DMPI), a clinical and commercial stage drug development company, has qualified to trade on OTCQX®, the best marketplace for established, global and growth companies.

Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO

DelMar Pharmaceuticals begins trading today on OTCQX under the symbol "DMPI."  U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

"We are proud to welcome DelMar Pharmaceuticals to the OTCQX marketplace," said R. Cromwell Coulson, President and CEO of OTC Markets Group. "DelMar Pharmaceuticals joins the growing group of U.S. and global companies that are choosing to trade on OTCQX to provide their investors with transparent trading and convenient access to their news and financial disclosure. We congratulate DelMar Pharmaceuticals' management team on this achievement and wish the company continued success."

DelMar Pharmaceuticals President and CEO Jeffrey Bacha commented, "DelMar is pleased to be joining the many top tier companies trading on the OTCQX marketplace.  This is an important step forward for our company as we advance our drug development programs toward commercialization and seek to deliver long term shareholder value."

Sichenzia Ross Friedman Ference LLP serves as DelMar Pharmaceuticals' Designated Advisor for Disclosure ("DAD") on OTCQX, responsible for providing professional guidance on OTCQX requirements and U.S. securities laws.

DelMar Pharmaceuticals is a clinical and commercial stage drug development company with a focus on the treatment of cancer.

About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates Open, Transparent and Connected financial marketplaces for 10,000 U.S. and global securities.  Through our OTC Link® ATS, we directly link a diverse network of broker-dealers that provide liquidity and execution services for a wide spectrum of securities.  We organize these securities into marketplaces to better inform investors of opportunities and risks – OTCQX®, The Best Marketplace; OTCQB®, The Venture Marketplace; and OTC Pink®, The Open Marketplace.  Our data-driven platform enables investors to easily trade through the broker of their choice at the best possible price and empowers a broad range of companies to improve the quality and availability of information for their investors.  To learn more about how we create better informed and more efficient financial marketplaces, visit www.otcmarkets.com.

OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.

Subscribe to the OTC Markets RSS Feed

Media Contact:
Saskia Sidenfaden, OTC Markets Group Inc., +1 (212) 896-4428, saskia@otcmarkets.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/otc-markets-group-welcomes-delmar-pharmaceuticals-to-otcqx-300002819.html

SOURCE OTC Markets Group Inc.



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today